Skip to main content
December 19, 2019
W. Clay Jackson, MD, DipTh, of the University of Tennessee College of Medicine in Memphis, discusses treatment approaches for patients with depression and substance use disorders.
December 05, 2019
W. Clay Jackson, MD, DipTh, explains the difference between major depressive disorder and major depressive disorder with mixed features.
November 07, 2019
Sanjay J. Mathew, MD, speaks about best practices for administering esketamine during his Psych Congress 2019 presentation "Top 5 Issues Clinicians Should Know about Ketamine Therapy."
November 01, 2019
In this video, forensic psychiatrist Phillip J. Resnick, MD discusses common traits in school shooters, misconceptions people have about school shooters, and how mental health clinicians can help prevent school shootings.
October 28, 2019
Michael Thase, MD, discusses when clinicians should consider using thyroid hormone as an antidepressant augmentation strategy and possible risks of the approach.
October 09, 2019
SAN DIEGO—While medications can address some of the symptoms of Alzheimer’s disease, maintaining a healthy lifestyle can delay its onset and slow progression of the disease, a geriatric psychiatry expert told attendees at Psych Congress 2019.
October 06, 2019
SAN DIEGO—There is no single profile of a school shooter, and potential threats must be evaluated based on the behavior of the student instead, forensic psychiatrist Phillip J. Resnick, MD, said at a Psych Congress 2019 Featured Session on school shooters.
October 05, 2019
SAN DIEGO—Mental health clinicians aren't talking to their patients enough about sexual dysfunction commonly associated with depression and its treatment, Anita Clayton. MD, stated at Psych Congress 2019.
October 05, 2019
SAN DIEGO—Psilocybin-assisted psychotherapy appears to have a beneficial and lasting effect on patient mood, but possible approval of the treatment remains some time away, a researcher said at Psych Congress 2019.
October 05, 2019
SAN DIEGO—A year’s treatment with the investigational drug ALKS 3831 was generally well-tolerated and demonstrated a safety profile that supports long-term use, according to study findings presented at Psych Congress 2019.
Back to Top